Alkem Laboratories Ltd, PN Gadgil Jewellers Ltd, and Granules India Ltd saw notable share price gains after announcing their Q1 FY26 results. Alkem and PN Gadgil delivered double-digit profit growth, while Granules India posted modest revenue gains despite a profit dip, reflecting mixed yet encouraging performances in their respective sectors.
The Indian equity markets witnessed a surge in investor activity on August 12, 2025, as leading companies from the pharmaceutical and jewellery sectors posted their April–June quarter earnings. Alkem Laboratories, PN Gadgil Jewellers, and Granules India all saw their shares climb on the back of fresh financial results, with market participants responding positively to the strong operational metrics and steady revenue trends. These announcements come at a time when corporate earnings are under close scrutiny, given global economic uncertainties and domestic market volatility.
Alkem Laboratories Ltd – Steady Growth in Pharma
Headquartered in Mumbai, Maharashtra, Alkem Laboratories Ltd is a leading pharmaceutical manufacturer with a presence across branded generics, formulations, and active pharmaceutical ingredients. The company serves both the domestic Indian market and international geographies, with a strong focus on therapeutic areas such as anti-infectives, gastro-intestinal treatments, cardiology, and pain management.
For Q1 FY26, Alkem Labs reported a consolidated net profit of ₹664 crore, marking a 22% year-on-year increase from ₹545 crore in Q1 FY25. Revenue from operations stood at ₹3,371 crore, reflecting steady growth in both domestic and export sales. Following the earnings release, Alkem’s stock surged 7.5% to ₹5,207 per share.
Over the past six months, the company’s shares have gained nearly 10%, although they remain down 7% year-to-date. In the longer term, Alkem has delivered a 77% gain over five years, cementing its position as a consistent performer in India’s pharmaceutical sector.
PN Gadgil Jewellers Ltd – Sparkling Profit Growth
With its headquarters in Pune, Maharashtra, PN Gadgil Jewellers Ltd is among India’s most iconic jewellery retailers, boasting a legacy of over 190 years. Known for blending traditional craftsmanship with modern design, the company offers a wide range of gold, diamond, and silver jewellery to customers across the country.
In Q1 FY26, PN Gadgil posted a net profit of ₹69 crore, almost doubling from ₹35 crore in the same quarter of the previous fiscal year. Revenue from operations increased 3% year-on-year to ₹171.5 crore. This jump in profitability was supported by stable gold prices, improved store performance, and seasonal buying trends.
The company’s shares rose 10%, hitting the upper circuit at ₹603.50 apiece. PN Gadgil debuted on the stock exchanges in September 2024 at ₹830 per share — a 73% premium to its IPO price. While the stock has corrected over 27% since its debut, the latest results signal potential for a turnaround in investor sentiment.
Also Read: Indian Companies to Pay Dividends on August 8, 2025
Granules India Ltd – Mixed Performance but Revenue Stability
Granules India Ltd, headquartered in Hyderabad, Telangana, is a vertically integrated pharmaceutical company producing formulation intermediates, active pharmaceutical ingredients, and finished dosage forms. The company has a significant export footprint, supplying to over 80 countries and partnering with major multinational drugmakers.
For Q1 FY26, Granules India reported a net profit of ₹112.64 crore, reflecting a 16% decline compared to ₹134.65 crore in Q1 FY25. However, revenue from operations grew nearly 3% year-on-year to ₹1,210 crore, driven by higher export orders and steady demand in select therapeutic segments.
Despite the profit drop, Granules India’s shares gained over 4% to ₹461 apiece post-results. The stock has faced short-term weakness, down 6% in the past month and 15% in six months, but remains a long-term gainer with a 49% rise over the past five years.
Market Reaction – Broader Indices and Sectoral Impact
On August 12, 2025, the BSE Sensex closed 278 points higher at 80,145, while the NSE Nifty 50 gained 91 points to settle at 24,367, supported by gains in the pharmaceutical and consumer discretionary sectors.
The Nifty Pharma Index advanced 1.9%, led by Alkem Laboratories and Granules India, while the BSE Consumer Durables Index rose 1.4%, driven by the rally in PN Gadgil Jewellers and other retail-linked counters.
Trading volumes in all three companies spiked significantly post-earnings announcements:
- Alkem Laboratories recorded volumes nearly 2.8 times its daily average, indicating strong institutional and retail participation.
- PN Gadgil Jewellers saw volumes surge over 5 times the average as the stock hit its upper circuit.
- Granules India witnessed volumes 2 times higher than usual, reflecting active short-term buying despite the profit decline.
Market analysts note that strong earnings in the first quarter often set the tone for sector sentiment in the subsequent quarters, particularly when supported by robust volume action and index participation.
The Q1 FY26 results from Alkem Laboratories, PN Gadgil Jewellers, and Granules India underscore the resilience of India’s pharmaceutical and consumer goods sectors, even amid broader market fluctuations. While Alkem and PN Gadgil showcased strong profit growth, Granules India’s stable revenue despite profit headwinds highlights the importance of diversification and global market reach. As investors weigh their next moves, these earnings will likely remain a key factor influencing near-term stock performance and sector sentiment.
READ MORE ON
